PAH IN SYSTEMIC SCLEROSIs
Systemic sclerosis (SSc) is an autoimmune connective tissue disease affecting multiple organs. PAH is a well-known cardiopulmonary complication of SSc.1 The estimated prevalence of SSc-PAH in Australia is 11.8%, making it the second most common type of PAH after the idiopathic form.1,2
SSc screening programs can reduce mortality5
Screening in SSc populations enables earlier diagnosis of PAH, facilitating earlier intervention and improving long-term survival.5 Annual cardiopulmonary screening is recommended in all patients with SSc, in order to identify patients who should have a right heart catheterisation to diagnose potential PAH.2
1. Aliquam blandit bibendum semper. Suspendisse molestie eget ex ornare laoreet. Nullam ornare nunc ac turpis dignissim posuere. Ut facilisis imperdiet ex, sit amet tincidunt diam lacinia malesuada.
Extra small button
Extra large button